Tatva Chintan Pharma Chem Limited — Investor Meet, 24-01-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Tatva Chintan posted strong Q3 FY26 results: revenue surged 53% YoY to 131.3 Cr, EBITDA soared 261% YoY to 25.5 Cr. PASC (+86% YoY) and SDA (+65% YoY) led the charge as chemical markets stabilize.

Management forecasts 20-30% revenue growth for FY26-27, targeting 20-22% EBITDA margins. A new 100 Cr Dahej plant begins commercial production by early March. Groundbreaking for a 250-275 Cr greenfield Jolva plant for new agro products is this quarter. First plant-scale trial order for Semiconductor Chemicals signals huge 2028 potential. Confident outlook focused on execution & innovation.